You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
嘉和生物-B(06998.HK):被許可人於其許可引入的新型T細胞銜接器用於自身免疫性疾病臨牀評估方面取得進展

格隆匯6月30日丨嘉和生物-B(06998.HK)宣佈,公司獲GB261的被許可人Candid Therapeutics, Inc.("被許可人")告知,被許可人於其許可引入的新型T細胞銜接器("TCE"或"GB261")用於自身免疫性疾病臨牀評估方面取得進展。首批患者已接受TCE給藥且耐受性良好。此外,TCE的皮下給藥配方已經確定。

GB261是一種針對B細胞上的CD20與T細胞上的CD3而開發的雙特異性抗體,可對錶達CD20的B細胞發揮T細胞介導的細胞毒性。GB261具備低CD3親和力,經優化後可降低T細胞過度活化的風險,同時維持強效且具選擇性的B細胞清除能力。公司已在中國及澳大利亞完成針對R/R B-NHL(R/R DLBCL和FL)進行的I/II期開放性多中心研究。

被許可人是一家處於臨牀階段的生物科技公司,專注於通過新型T細胞銜接器平臺改變自身免疫性及炎症性疾病的治療方法。於2024年8月2日,集團已授予TRC 2004, Inc.全球獨家許可(不包括中國大陸、香港、澳門及臺灣),以開發、使用、製造、商業化及以其他方式利用GB261 (CD20/CD3,雙特異性抗體)。TRC 2004, Inc.於所述許可項下的權利,其後於被許可人(即Candid Therapeutics,Inc.)與TRC 2004, Inc.於2024年8月合併後,於2024年12月轉讓予被許可人。被許可人擁有經驗豐富的管理團隊,包括首席執行官Ken Song博士。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account